Emerging concepts in disease management: a role for antimicrobial therapy in coronary artery disease

Expert Opinion on Pharmacotherapy
S E Girard, Z Temesgen

Abstract

Coronary artery disease, the leading cause of morbidity and mortality in developed countries, is a chronic inflammatory process that develops in response to a variety of injuries. A number of microbial organisms have been implicated in its pathogenesis. The strongest evidence to date for an association between an infectious agent and coronary heart disease is that for Chlamydia pneumoniae. Evidence implicating other microbial organisms is much less compelling. Sero-epidemiological and pathological data have linked infection with C. pneumoniae to atherosclerotic coronary artery disease. A possible mechanism by which C. pneumoniae may participate in the pathogenesis of atherosclerosis is through immune activation and the initiation of a chronic inflammatory state in the infected arterial wall. Locally secreted inflammatory cytokines trigger a cascade of secondary cellular processes that lead to characteristic structural changes. C. pneumoniae has been detected in atherosclerotic plaques and in the serum of patients with coronary artery disease. It induces foam cells (the hallmark of early atherosclerosis) and it markedly accelerates this disease process in animal models. C. pneumoniae has been associated with elevated levels of i...Continue Reading

References

Jul 1, 1992·The Journal of Infection·P Saikku
Jul 1, 1992·JAMA : the Journal of the American Medical Association·D H ThomJ R Daling
Jul 18, 1995·Proceedings of the National Academy of Sciences of the United States of America·C C KuoE P Benditt
Oct 1, 1993·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·C C KuoJ T Grayston
Dec 1, 1994·The Journal of Antimicrobial Chemotherapy·P J Cook, D Honeybourne
Aug 18, 1994·The New England Journal of Medicine·G LiuzzoA Maseri
Jan 1, 1995·British Heart Journal·E W LeathamA J Camm
Apr 1, 1994·Microbial Pathogenesis·S S Kaukoranta-TolvanenM Leinonen
Apr 1, 1993·The Journal of Infectious Diseases·C C KuoJ T Grayston
Jan 1, 1997·Journal of Clinical Microbiology·I W FongJ Mahony
Apr 1, 1997·The Journal of Infectious Diseases·T C MoazedL A Campbell
Mar 14, 1998·The Journal of Infectious Diseases·M V Kalayoglu, G I Byrne
Jan 14, 1999·The New England Journal of Medicine·R Ross
Feb 10, 1999·JAMA : the Journal of the American Medical Association·C R MeierH Jick
Jun 16, 1999·The Annals of Pharmacotherapy·S S Carlisle, M C Nahata

❮ Previous
Next ❯

Citations

Jun 24, 2003·Atherosclerosis·David J LambGordon A A Ferns
May 23, 2003·Antimicrobial Agents and Chemotherapy·Hiroyuki YamaguchiYoshimasa Yamamoto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Related Papers

The Journal of Antimicrobial Chemotherapy
A PascualE J Perea
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
M V Stolk-Engelaar, M F Peeters
© 2021 Meta ULC. All rights reserved